|
Cephalon, Inc. - Company Profile Snapshot
| Company Profile: |
Cephalon, Inc. |
| Ticker: |
CEPH |
| Exchanges: |
NAS |
| 2008 Sales: |
1,974,600,000 |
| Major Industry: |
Drugs, Cosmetics & Health Care |
| Sub Industry: |
Ethical Drug Manufacturers |
| Country: |
UNITED STATES |
| Employees: |
2780 |
Business Description
Cephalon, Inc.. The Group's principal activity is to discover, develop and market products to treat neurological disorders and cancers. The Group researches to develop suitable drugs in treatment of neurological disorders like ALS, narcolepsy, peripheral neuropathies, head and spinal injury, Alzheimer's and stroke. Its products are Provigil(R),FENTORA, ACTIQ (R), NUVIGIL and GABITRIL (R). Provigil tablets are used by those suffering from excessive daytime sleepiness associated with narcolepsy; ACTIQ (R), for the management of breakthrough cancer pain in opioid tolerant patients and the further development of Gabitril (R), an adjunctive treatment for partial seizures associated with epilepsy. The Group operates in the United States, France, the United Kingdom, Germany, Italy, the Netherlands and Switzerland.
|
Not the Report you are looking for?
Click here for more browsing options.
|
The following information is available to subscribers or can be accessed by purchasing the Company Profile Report:
|
- Address (mailing), Phone Number, Web Address
- Earnings/Dividends
- Employees
- Exchanges Listed
- Financial Ratio Analysis |
- Recent Stock Performance
- Sales (recent year)
- Senior Officers
- Shareholder Information
- Stock Analysis Summary |
Layout and Content of a Typical Report
|
|
|
|
|
